戻る

Novo Nordisk data show fewer heart events after semaglutide dose increases

  • Novo Nordisk presented real-world data comparing semaglutide dose increases with tirzepatide switches.
  • Patients increasing semaglutide experienced fewer major cardiovascular events than those switching treatments.
  • The retrospective analysis drew on records from 63, according to the available source.

Novo Nordisk A/S (NVO) unveiled real-world data on Tuesday indicating that patients who increased their semaglutide dose experienced fewer major cardiovascular events than patients who switched to Eli Lilly and Co.’s (LLY) rival tirzepatide. The retrospective analysis drew on records from 63, although the available source ends before specifying what the figure refers to.

当サイトの情報はAIを用いて生成されており、正確性を保証するものではありません。 参考情報としてご活用ください。